Copyright
©The Author(s) 2016.
World J Stem Cells. Jul 26, 2016; 8(7): 223-230
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Published online Jul 26, 2016. doi: 10.4252/wjsc.v8.i7.223
Parameter | < HPG (n) at baseline | HPG n (%) at T1 |
FBS | 95 | 61 (64.2) |
HbA1c | 93 | 44 (47.3) |
Insulin level | 91 | 60 (65.9) |
Insulin with medication | 92 | 24 (26.1) |
Medication level | 93 | 25 (26.9) |
Post-prandial blood insulin 60 min | 95 | 58 (61.1) |
Post-prandial blood sugar | 95 | 58 (61.1) |
Pre-dinner | 95 | 55 (57.9) |
Secondary complication | 84 | 27 (32.1) |
Serum insulin | 94 | 74 (78.7) |
Serum peptide | 90 | 65 (72.2) |
Parameter | Patients (n) affected at baseline | Improved n (%) |
FBS | 95 | 93 (97.9) |
HbA1c | 93 | 90 (96.8) |
Insulin level | 91 | 88 (96.7) |
Insulin with medication | 92 | 88 (95.7) |
Medication level | 93 | 82 (88.2) |
Post-prandial blood insulin 60 min | 95 | 92 (96.8) |
Post-prandial blood sugar | 95 | 92 (96.8) |
Pre-dinner | 95 | 93 (97.9) |
Secondary complication | 84 | 79 (94.0) |
Serum insulin | 94 | 80 (85.1) |
Serum peptide | 90 | 87 (96.7) |
- Citation: Shroff G. Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus. World J Stem Cells 2016; 8(7): 223-230
- URL: https://www.wjgnet.com/1948-0210/full/v8/i7/223.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v8.i7.223